Cost-effectiveness of upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes
- PMID: 17222743
- DOI: 10.1016/j.jacc.2006.10.020
Cost-effectiveness of upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes
Comment on
-
The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.J Am Coll Cardiol. 2006 Feb 7;47(3):529-37. doi: 10.1016/j.jacc.2005.08.070. Epub 2006 Jan 18. J Am Coll Cardiol. 2006. PMID: 16458131
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources